Skip to main content

Donna Niedzwiecki

Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
Duke Box 2717, Durham, NC 27710
2424 Erwin Rd, Hock Plaza, Suite 802, Rm 8040, Durham, NC 27705

Scholarly Works - Conferences


Using Natural Language Processing to Assess Goals-of-Care Conversations for Patients With Cancer.

Conference JCO Clin Cancer Inform · October 2025 PURPOSE: Goals-of-care (GOC) discussions during advanced serious illness and end-of-life (EOL) care are critical. Institutions are increasingly tracking the frequency and timing of GOC documentation, but large-scale content assessments have been limited. W ... Full text Link to item Cite

Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.

Conference Ann Surg Oncol · February 2025 BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ... Full text Link to item Cite

Long-term risk of carotid stenosis and cerebrovascular disease after radiation therapy for head and neck cancer.

Conference Cancer · January 1, 2025 BACKGROUND: Recipients of radiation therapy (RT) for head and neck cancer (HNC) are at significantly increased risk for carotid artery stenosis (CAS) and cerebrovascular disease (CVD). We sought to determine (1) cumulative incidences of CAS and CVD among H ... Full text Link to item Cite

Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).

Conference Journal of Clinical Oncology · June 1, 2024 2668Background: Peritoneal surface malignancies (PSM) constitute a group of difficult-to-treat metastatic diseases that respond poorly to standard chemotherapy. Talimogene Laherparepvec (T-VEC), the first FDA-approved oncolytic virus (OV), demonstrates pot ... Full text Cite

Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of survival and patterns of recurrence in a prospective, phase II single-arm trial.

Conference Journal of Clinical Oncology · January 1, 2024 Background: Locally advanced esophagogastric adenocarcinoma (EGA) is commonly treated with neoadjuvant chemoradiation (CRT) prior to surgical resection. Adjuvant immunotherapy has been shown to improve outcomes for these patients. The primary objective of ... Full text Cite

Current approach to health care transition and integration into adult care for pediatric liver transplant recipients: A call for partnership.

Conference Clin Transplant · August 2023 Despite the increased risk of non-adherence, allograft rejection, and mortality following transfer from pediatric to adult care in liver transplantation (LT), there is no standardized approach to health care transition (HCT). Two electronic national survey ... Full text Link to item Cite

Clinical Predictors of a Positive Ct Angiogram Study Used for the Evaluation of Acute Gastrointestinal Hemorrhage.

Conference Dig Dis Sci · January 2023 BACKGROUND: Acute gastrointestinal (GI) bleeding is one of the leading causes of emergency department visits and hospital admissions. CT angiography (CTA) has had an expanding role in the evaluation of acute GI bleeding because it is rapidly performed, wid ... Full text Link to item Cite

Machine Learning Algorithm Prospectively Predicts Survival for High-Risk Patients Undergoing Radiotherapy: A Survival Analysis of SHIELD-RT.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Mortality prediction is critical to appropriate cancer care planning. This has become a topic of interest, with machine learning (ML) tools demonstrating accurate binary predictions for mortality at specific time points. There ... Full text Cite

Interpreting Post-SBRT Lung Imaging: A Comparison of Radiology and Radiation Oncology Impressions.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Stereotactic body radiation therapy (SBRT) is an established treatment option for stage I non-small cell lung cancer. SBRT often causes acute inflammatory changes in the lung as well as chronic fibrosis. These radiologic findin ... Full text Cite

Oligometastases Treated With an Elective Simultaneous Integrated Boost Have Reduced Marginal Recurrence Rates.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Radiation is increasingly used to treat oligometastatic patients (OM). Following metastasis directed radiation therapy, progression in nearby nodal basins or bones is common. We previously reported clinical outcomes of OM treat ... Full text Cite

Impact of Target Volume and Image Guidance on Post-Prostatectomy Patients Treated With Intensity Modulated Radiation Therapy.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Post-operative radiotherapy (PORT) is utilized in select prostate cancer patients. IMRT has been associated with improved dosimetry and acute toxicity. Smaller treatment margins for PORT have been recommended when using image g ... Full text Cite

Survey of Healthcare Providers Utilization and Perception of Telehealth On-Treatment Visits During COVID-19 Pandemic.

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Patients undergoing radiotherapy during the COVID-19 pandemic have experienced unique changes to care, including increased use of telehealth for radiotherapy on-treatment visits (OTVs). The objective of this study was to determ ... Full text Cite

The Role of Hypofractionated Radiation Therapy in the Management of Unresectable Hepatocellular Carcinoma (HCC).

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)Management of HCC without surgical resection or transplantation is poorly defined with no standard. Stereotactic body radiation therapy (SBRT) or hypofractionated image-guided radiotherapy (HIGRT), is an evolving, non-invasive, ... Full text Cite

Toxicity and Dosimetric Parameters of Ablative Radiation Therapy in the Management of Patients with Child-Pugh B/C Liver Function and Unresectable Hepatocellular Carcinoma (HCC).

Conference International journal of radiation oncology, biology, physics · November 2021 Purpose/objective(s)To date there is no clear standard non-surgical therapeutic option for HCC patients. Ablative radiation therapy (SBRT/HIGRT) is an emerging non-invasive treatment for patients with HCC. However, there is concern about the risk ... Full text Cite

Use of Skeletal Muscle Index as a Predictor of Wait-List Mortality in Patients With End-Stage Liver Disease.

Conference Liver Transpl · September 2020 The aim of this study is to validate a proposed definition of sarcopenia in predicting wait-list mortality. We retrospectively evaluated 355 adults (age โ‰ฅ18 years) with cirrhosis listed for first-time LT from January 1, 2010, to April 1, 2018 from our cent ... Full text Link to item Cite

Esophageal contractility increases and gastroesophageal reflux does not worsen after lung transplantation.

Conference Dis Esophagus · December 13, 2019 Gastroesophageal reflux and esophageal dysmotility are common in patients with advanced lung disease and are associated with allograft dysfunction after lung transplantation. The effect of transplantation on reflux and esophageal motility is unclear. The a ... Full text Link to item Cite

1089โ€ƒHypophosphatemia in Patients With Alcoholic Hepatitis

Conference American Journal of Gastroenterology · October 2019 INTRODUCTION:Patients with alcoholic hepatitis suffer from high rates of malnutrition and are at risk for hypophosphatemia due to poor dietary intake, renal wasting, and r ... Full text Cite

Accuracy of a Natural Language Processing Pipeline to Identify Patient Symptoms during Radiation Therapy

Conference International Journal of Radiation Oncology*Biology*Physics · September 2019 Full text Cite

A phase I study of gemcitabineโ€‰+โ€‰dasatinib (gd) or gemcitabineโ€‰+โ€‰dasatinibโ€‰+โ€‰cetuximab (GDC) in refractory solid tumors.

Conference Cancer Chemother Pharmacol · June 2019 PURPOSE: This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabineโ€‰+โ€‰dasatinib (GD) and gemcitabineโ€‰+โ€‰dasatinibโ€‰+โ€‰cetuximab (GDC) in advanced solid tumor patients. METHODS: This st ... Full text Link to item Cite

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).

Conference Journal of Clinical Oncology · May 20, 2019 4005 Background: Patients (pts) with progressive advanced well-differentiated neuroendocrine tumors arising outside of the pancreas have limited systemic treatment options. Pazopanib (PZ) is an oral multi-kinase inhibitor with ac ... Full text Cite

Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2019 3035 Background: Energy balance-associated biomarkers such as insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) have been associated with risk and prognosis of various malignancies. Their relationship to diseas ... Full text Cite

Adaptive IMRT Planning Improves Pharyngeal Sparing for Oropharyngeal Cancer

Conference International Journal of Radiation Oncology*Biology*Physics · November 2018 Full text Cite

TIPS Outcomes According to Race and Ethnicity

Conference AMERICAN JOURNAL OF GASTROENTEROLOGY · October 1, 2018 Link to item Cite

Measuring the Quality of Gastric Cancer Care in the United

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2018 Link to item Cite

Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).

Conference Journal of Clinical Oncology · February 1, 2018 638 Background: Colorectal cancer (CRC) is a heterogeneous disease with distinct molecular subtypes in part based on RAS mutational status. It is plausible that RAS mutations are differentially distributed between CC and AA and m ... Full text Cite

BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.

Conference Journal of Clinical Oncology · February 1, 2018 TPS873 Background: Initial treatment of metastatic colorectal cancer (mCRC) involves a 5-fluorouracil based chemotherapy regimen, often in combination with anti-VEGF therapy. Upon disease progression, multiple studies have sugges ... Full text Cite

Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.

Conference Biol Blood Marrow Transplant · November 2017 Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation ( ... Full text Link to item Cite

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Conference Journal of Clinical Oncology · June 20, 2017 LBA1 Background: Since 2004, 6 months (m) of oxaliplatin (oxali)-based treatment has been the standard of care as adjuvant therapy for stage III CC. Since oxali is associated with cumulative neurotoxicity, shorter duration of adj ... Full text Cite

American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2017 10006 Background: The ACS Nutrition and Physical Activity Guidelines for Cancer Survivors include: 1) healthy body weight; 2) physical activity; and 3) a diet high in vegetables, fruits, and whole grains. It is not known whether ... Full text Cite

A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).

Conference Journal of Clinical Oncology · May 20, 2017 TPS3624 Background: To improve survival for patients with mCRC, efforts are needed to identify and treat actionable genomic alterations. HER2 is amplified in approximately 5-8% of patients with KRAS and NRAS (RAS) wild-type mCRC. ... Full text Cite

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2017 3511 Background: CALGB 80405 was a randomized Ph3 trial showing no OS or PFS difference in mCRC pts treated with Bevacizumab (BV) or Cetuximab (Cet) in the first line. A Nanostring platform was used to determine the CMS classific ... Full text Cite

Somatic DNA mutations, MSI status, mutational load (ML): Association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

Conference Journal of Clinical Oncology · May 20, 2017 3504 Background: CALGB 80405 was a randomized phase III trial that found no difference in OS in first-line mCRC pts treated with either bevacizumab (Bev) or cetuximab (Cet). Primary tumor DNA from 361 pts, including KRAS mutant ( ... Full text Cite

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Conference Journal of Clinical Oncology · May 20, 2017 LBA1 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Sunday, June 4, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Cl ... Full text Cite

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.

Conference Journal of Clinical Oncology · May 20, 2017 3528 Background: CALGB 80405 is a phase III clinical trial of FOLFOX and FOLFIRI w/ randomly assigned cetuximab or bevacizumab. Novel machine learning approaches to the study dataset provide valuable insights into CRC prognosis a ... Full text Cite

Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

Conference Journal of Clinical Oncology · February 1, 2017 1 Background: To determine whether changing chemotherapy (CT) during pre-op chemoradiation (CRT) based on response to induction CT by 18F-fluoro-deoxyglucose PET imaging can lead to improved pathologic comple ... Full text Cite

Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).

Conference Journal of Clinical Oncology · February 1, 2017 659 Background: Regular physical activity (PA) is associated with reduced risk of recurrence and mortality in non-metastatic colorectal cancer. Its influence on patients with metastatic colorectal cancer (mCRC) is largely unexplo ... Full text Cite

Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).

Conference Journal of Clinical Oncology · February 1, 2017 585 Background: Long-chain omega-3 fatty acids (LCN-3 FA) may prevent colon cancer (CC) progression, but data in humans are lacking. We hypothesized that LCN-3 FA and dark meat fish intake after CC diagnosis would be associated w ... Full text Cite

X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).

Conference Journal of Clinical Oncology · February 1, 2016 687 Background: Patients (pts) with chemotherapy refractory mCRC have a poor prognosis, with a median survival of approximately 6 months (mos). Ziv-aflibercept is FDA-approved in combination with FOLFIRI for the 2nd Full text Cite

Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2015 507 Background: Prospective epidemiologic data suggest that higher levels of 25-hydroxyvitamin D [25(OH)D] are associated with improved survival in patients with colorectal cancer (CRC), however, the relationship between 25(OH)D ... Full text Cite

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Conference Journal of Clinical Oncology · January 20, 2014 448 Background: Previously, we identified potential predictive biomarkers of C sensitivity related to EGFR signaling from archived tumor tissue from CALGB 80203. Due to the fact that blood-based markers are more convenient and ca ... Full text Cite

Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.

Conference Journal of Clinical Oncology · January 20, 2014 455 Background: Only 15-25% of pts with stage II colon cancer (CC) experience recurrence and conventional staging methods neither allow accurate identification of low (L) and high-risk (H) subgroups nor predict benefit of adjuvan ... Full text Cite

Quality of life (QOL) and toxicity among patients in CALGB 80405

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2013 Link to item Cite

A novel interaction of genotype, gender, and adjuvant treatment in survival after resection of stage III colon cancer: Results of CALGB 89803.

Conference Journal of Clinical Oncology · February 1, 2012 452 Background: The p53 tumor suppressor gene is frequently mutated in colorectal cancer, but reports on the effect of p53 mutations on response to adjuvant chemotherapy and survival are inconclusive. This study investigates whet ... Full text Cite

Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

Conference Blood · November 16, 2006 AbstractWe evaluated the feasibility, safety, and effectiveness of an intense IC regimen including ASCT in pts with untreated MCL up to age 70. The primary end-point was 2-year progression free survival (PFS ... Full text Cite

Multivariate Analysis of Patient and Graft Specific Factors among 330 Recipients of Unrelated Cord Blood Transplant (UCBT) To Predict Risk of Death from Opportunistic Infections in the First 6 Months after UCBT.

Conference Blood · November 16, 2006 AbstractUnrelated umbilical cord blood transplantation (UCBT) is a suitable option for those who lack HLA-matched sibling donors. However, opportunistic infections (OI), with the majority detected in the fir ... Full text Cite

Outcome and Immune Reconstitution Following T Cell Depleted Nonmyeloablative Allogeneic Transplantation Using Matched Donors.

Conference Blood · November 16, 2005 AbstractTo minimize toxicity and monitor immune recovery without interference of long term use of immunosuppressive agents, we have investigated T-cell depleted, nonmyeloablative allogeneic therapy using mat ... Full text Cite

Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.

Conference Blood · November 16, 2004 AbstractTopoisomerase enzymes are critical components of genomic replication and function to minimize torsional stress on DNA. Inhibition of topoisomerase function leads to DNA strand breaks followed by apop ... Full text Cite

Dose Dense, High Intensity Induction Therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem Cell Transplantation(AHSCT) for Mantle Cell Lymphoma (MCL).

Conference Blood · November 16, 2004 AbstractIntroduction: Though response may occur with standard therapy, early relapse is common with advanced stage MCL, suggesting the importance of drug resistance in this disease process.It appears that re ... Full text Cite

Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. A Preliminary Report.

Conference Blood · November 16, 2004 AbstractWe evaluated the feasibility, safety, and effectiveness of an intense IC regimen including ASCT in pts with untreated MCL up to age 70. Pts with MCL confirmed by central pathology review plus one add ... Full text Cite

Dendritic and T Cell Subsets Correlate with the Development and Site of Acute GVHD Following Unrelated Cord Blood Transplantation. A Multivariate Analysis of Host, Graft, and Day+50 Immune Profile.

Conference Blood · November 16, 2004 AbstractHLA-mismatched unrelated umbilical cord blood transplantation (uUCBT) is a suitable option for those who lack HLA-matched sibling donors. Although UCB T cells mount significantly less cytotoxicity an ... Full text Cite

Sentinel node staging of resectable colon cancer: Results of CALGB 80001.

Conference JOURNAL OF CLINICAL ONCOLOGY · July 15, 2004 Link to item Cite